Speakers
Alexandre Di Paolo
Senior Business Development Manager
TriLink BioTechnologies
Day Two
Thursday 27th January 2021
10:45 am | mRNA Modifications that Matter: Modified Uridine as a Therapeutic Tool
10:45 am | mRNA Modifications that Matter: Modified Uridine as a Therapeutic Tool
Alexandre Di Paolo
Senior Business Development Manager
TriLink BioTechnologies
Allison August
VP, Clinical Development, Infectious Diseases
Moderna
Day One
Wednesday 26th January 2021
2:15 pm | Lipid-Encapsulated mRNA Delivery of a Monoclonal Antibody with Neutralizing Activity Against Chikungunya Virus: Results From a Phase 1 Trial
5:00 pm | Panel Discussion
2:15 pm | Lipid-Encapsulated mRNA Delivery of a Monoclonal Antibody with Neutralizing Activity Against Chikungunya Virus: Results From a Phase 1 Trial
5:00 pm | Panel Discussion
Allison August
VP, Clinical Development, Infectious Diseases
Moderna
Amar Deep Sharma
Group Leader
Hannover Medical School
Day One
Wednesday 26th January 2021
12:45 pm | Discovering Novel Methods to Promote Protein Replacement in Chronic End-Stage Disease
12:45 pm | Discovering Novel Methods to Promote Protein Replacement in Chronic End-Stage Disease
Amar Deep Sharma
Group Leader
Hannover Medical School
Andreas Kuhn
Senior VP - RNA Biochemistry & Manufacturing
BioNTech
Day One
Wednesday 26th January 2021
8:15 am | Chair’s Opening Remarks
8:15 am | Chair’s Opening Remarks
Andreas Kuhn
Senior VP - RNA Biochemistry & Manufacturing
BioNTech
Arun Kumar
Preclinical Vaccines Development Lead
Coalition for Epidemic Preparedness Innovations (CEPI)
Day One
Wednesday 26th January 2021
8:30 am | Landscaping mRNA- Based Vaccine Technologies for the Future
5:00 pm | Panel Discussion
5:00 pm | Panel Discussion
8:30 am | Landscaping mRNA- Based Vaccine Technologies for the Future
Arun Kumar
Preclinical Vaccines Development Lead
Coalition for Epidemic Preparedness Innovations (CEPI)
Carsten Rudolph
CEO
Ethris
Day Two
Thursday 27th January 2021
5:00 pm | Panel Discussion
5:00 pm | Panel Discussion
Carsten Rudolph
CEO
Ethris
Christian Hotz
Director - In Situ Therapy
BioNTech
Day One
Wednesday 26th January 2021
11:15 am | Local Immunotherapy with Cytokine-Encoding mRNAs for Immuno-Oncology
11:15 am | Local Immunotherapy with Cytokine-Encoding mRNAs for Immuno-Oncology
Christian Hotz
Director - In Situ Therapy
BioNTech
Danilo Casimiro
CSO
Sanofi Pasteur
Day One
Wednesday 26th January 2021
5:00 pm | Panel Discussion
6:15 pm | Chair’s Closing Remarks & End of Conference Day One
6:15 pm | Chair’s Closing Remarks & End of Conference Day One
5:00 pm | Panel Discussion
Danilo Casimiro
CSO
Sanofi Pasteur
Dariush Mohammadyani
Senior Scientist
Johnson & Johnson
Day Two
Thursday 27th January 2021
5:30 pm | Computational Approaches to Develop Next-Generation mRNA- Based Therapeutic Delivery Methods
5:30 pm | Computational Approaches to Develop Next-Generation mRNA- Based Therapeutic Delivery Methods
Dariush Mohammadyani
Senior Scientist
Johnson & Johnson
Darwin Asa
Market Development Manager
ThermoFisher Scientific
Day Two
Thursday 27th January 2021
3:30 pm | Plan Now or Fail Later: Why Raw Materials Matter
3:30 pm | Plan Now or Fail Later: Why Raw Materials Matter
Darwin Asa
Market Development Manager
ThermoFisher Scientific
David M. Brown
Associate Director
RNAimmune
Day One
Wednesday 26th January 2021
5:30 pm | Engineering and Results of Next-Generation COVID-19 Vaccines - Sponsored by Codex DNA
5:30 pm | Engineering and Results of Next-Generation COVID-19 Vaccines - Sponsored by Codex DNA
David M. Brown
Associate Director
RNAimmune
Drew Weissman
Professor - Vaccine Research
University of Pennsylvania, Perelman School of Medicine
Day Two
Thursday 27th January 2021
12:15 pm | Tissue Specific Targeting of mRNA to Increase Therapeutic & Vaccine Efficacy
12:15 pm | Tissue Specific Targeting of mRNA to Increase Therapeutic & Vaccine Efficacy
Drew Weissman
Professor - Vaccine Research
University of Pennsylvania, Perelman School of Medicine
Dushyant Varshney
Executive VP & CTO
Arcturus Therapeutics
Day One
Wednesday 26th January 2021
4:30 pm | Rapid Commercialization & Technology Transfer of mRNA Vaccines & Therapeutics
5:00 pm | Panel Discussion
5:00 pm | Panel Discussion
4:30 pm | Rapid Commercialization & Technology Transfer of mRNA Vaccines & Therapeutics
Dushyant Varshney
Executive VP & CTO
Arcturus Therapeutics
Elaine Peters
Director - Analytical Lead
Genentech
Elaine Peters
Director - Analytical Lead
Genentech
Heinrich Haas
VP – Formulation & Delivery
BioNTech
Day Two
Thursday 27th January 2021
9:15 am | Approaches Towards Next Generation mRNA Delivery Systems
9:15 am | Approaches Towards Next Generation mRNA Delivery Systems
Heinrich Haas
VP – Formulation & Delivery
BioNTech
Henrik Ihre
Global Director Strategic Technologies
Cytiva
Day One
Wednesday 26th January 2021
12:15 pm | Manufacturing Considerations of mRNA- Based Therapeutics
12:15 pm | Manufacturing Considerations of mRNA- Based Therapeutics
Henrik Ihre
Global Director Strategic Technologies
Cytiva
Jacob Becraft
Co-Founder & CEO
Strand Therapeutics
Day Two
Thursday 27th January 2021
5:00 pm | Panel Discussion
5:00 pm | Panel Discussion
Jacob Becraft
Co-Founder & CEO
Strand Therapeutics
Jaspreet Khurana
Director - Platform & Discovery
Strand Therapeutics
Day Two
Thursday 27th January 2021
1:30 pm | Programming mRNA to Enable Cell-Type Specific Target Expression
1:30 pm | Programming mRNA to Enable Cell-Type Specific Target Expression
Jaspreet Khurana
Director - Platform & Discovery
Strand Therapeutics
Julian Mochayedi
Strategic Marketing Manager – mRNA solutions
Merck KGaA
Day Two
Thursday 27th January 2021
9:45 am | Keys to Successful mRNA Manufacturing from Development, Purification and Lipid Formulation to Facility Design
9:45 am | Keys to Successful mRNA Manufacturing from Development, Purification and Lipid Formulation to Facility Design
Julian Mochayedi
Strategic Marketing Manager – mRNA solutions
Merck KGaA
Lloyd Jeffs
Senior Director of Pharmaceutical Development
Precision NanoSystems
Day One
Wednesday 26th January 2021
2:45 pm | Accelerated Development of Self-Amplifying mRNA (saRNA) Vaccines
2:45 pm | Accelerated Development of Self-Amplifying mRNA (saRNA) Vaccines
Lloyd Jeffs
Senior Director of Pharmaceutical Development
Precision NanoSystems
Lucia Lapazio
Group Lead - mRNA
Sanofi
Day One
Wednesday 26th January 2021
9:30 am | Advancing Strategies & CMC for mRNA- Based Therapeutic Development
9:30 am | Advancing Strategies & CMC for mRNA- Based Therapeutic Development
Lucia Lapazio
Group Lead - mRNA
Sanofi
Marcus Wilhelmsson
Professor Chalmers
University of Technology
Day Two
Thursday 27th January 2021
12:45 pm | Monitoring Functional Cellular Uptake of mRNA Using Native-Like Fluorophores & Challenges with Expanding the Methodology to In Vivo
12:45 pm | Monitoring Functional Cellular Uptake of mRNA Using Native-Like Fluorophores & Challenges with Expanding the Methodology to In Vivo
Marcus Wilhelmsson
Professor Chalmers
University of Technology
Maria-Teresa Peracchia
Global Head Drug Delivery and Product Integration
Sanofi
Day Two
Thursday 27th January 2021
6:00 pm | Chair’s Closing Remarks & End of mRNA- Based Therapeutics Summit Europe
9:00 am | Chair’s Opening Remarks
6:00 pm | Chair’s Closing Remarks & End of mRNA- Based Therapeutics Summit Europe
9:00 am | Chair’s Opening Remarks
Maria-Teresa Peracchia
Global Head Drug Delivery and Product Integration
Sanofi
Mathieu Ghadanfar
CMO
Ziphius Vaccines
Day One
Wednesday 26th January 2021
3:15 pm | Reconceptualizing Vaccine Approaches Across the Development Pipeline
5:00 pm | Panel Discussion
5:00 pm | Panel Discussion
3:15 pm | Reconceptualizing Vaccine Approaches Across the Development Pipeline
Mathieu Ghadanfar
CMO
Ziphius Vaccines
Michael Wourms
SVP, Head of mRNA Business Unit
Arranta Bio
Day Two
Thursday 27th January 2021
1:15 pm | Integrating a Fragmented mRNA- Based Therapies Supply Chain
1:15 pm | Integrating a Fragmented mRNA- Based Therapies Supply Chain
Michael Wourms
SVP, Head of mRNA Business Unit
Arranta Bio
Michiel Lodder
CEO
20Med Therapeutics
Day Two
Thursday 27th January 2021
10:15 am | Harnessing an Alternative Non-Viral Polymer- Based Drug Delivery System for mRNA- Based Therapeutics
10:15 am | Harnessing an Alternative Non-Viral Polymer- Based Drug Delivery System for mRNA- Based Therapeutics
Michiel Lodder
CEO
20Med Therapeutics
Nargisse El Hajjami
Senior Consultant - Novel Modalities BioProcessing Strategy Operationalization
Merck KGaA
Day Two
Thursday 27th January 2021
9:45 am | Keys to Successful mRNA Manufacturing from Development, Purification and Lipid Formulation to Facility Design
9:45 am | Keys to Successful mRNA Manufacturing from Development, Purification and Lipid Formulation to Facility Design
Nargisse El Hajjami
Senior Consultant - Novel Modalities BioProcessing Strategy Operationalization
Merck KGaA
Patrick Finn
Senior Director - Rare Diseases
Moderna
Day Two
Thursday 27th January 2021
3:00 pm | Strategies of mRNA- Based Therapeutics to Replace Enzymes for Rare Diseases
3:00 pm | Strategies of mRNA- Based Therapeutics to Replace Enzymes for Rare Diseases
Patrick Finn
Senior Director - Rare Diseases
Moderna
Rok Sekirnik
Head Process Development for mRNA and pDNA
BIA Separations
Day One
Wednesday 26th January 2021
9:00 am | mRNA: Removing Bottlenecks in Process Development & Manufacturing
9:00 am | mRNA: Removing Bottlenecks in Process Development & Manufacturing
Rok Sekirnik
Head Process Development for mRNA and pDNA
BIA Separations
Roland Pach
Global Expert Cell & Gene Therapy Analytics
Roche Pharmaceuticals
Roland Pach
Global Expert Cell & Gene Therapy Analytics
Roche Pharmaceuticals
Sophia Shamsi
Research Analyst
Beacon Targeted Therapies
Day One
Wednesday 26th January 2021
3:45 pm | The mRNA Landscape & Beyond
3:45 pm | The mRNA Landscape & Beyond
Sophia Shamsi
Research Analyst
Beacon Targeted Therapies
Thomas Langenickel
CMO
Ethris
Day One
Wednesday 26th January 2021
11:45 am | Targeting Immunomodulation with mRNA- Based Therapeutics
11:45 am | Targeting Immunomodulation with mRNA- Based Therapeutics
Thomas Langenickel
CMO
Ethris
Tom Barnes
CEO
Orna Therapeutics
Day One
Wednesday 26th January 2021
5:45 pm | The Therapeutic Potential of oRNA
5:45 pm | The Therapeutic Potential of oRNA
Day Two
Thursday 27th January 2021
5:00 pm | Panel Discussion
5:00 pm | Panel Discussion
Tom Barnes
CEO
Orna Therapeutics
Vittorio Sebastiano
Co-founder & Scientific Advisory Board Chairman
Turn Biotechnologies
Day Two
Thursday 27th January 2021
5:00 pm | Panel Discussion
4:00 pm | Epigenetic Reprogramming of Aging (ERA): mRNA- Based Solution for Age-Related Diseases
4:00 pm | Epigenetic Reprogramming of Aging (ERA): mRNA- Based Solution for Age-Related Diseases
5:00 pm | Panel Discussion
Vittorio Sebastiano
Co-founder & Scientific Advisory Board Chairman
Turn Biotechnologies
Volker Germaschewski
Senior VP - Research & Development
eTheRNA Immunotherapies NV
Day One
Wednesday 26th January 2021
10:00 am | Engineering the Future of mRNA Therapies
10:00 am | Engineering the Future of mRNA Therapies
Volker Germaschewski
Senior VP - Research & Development
eTheRNA Immunotherapies NV